FEIBA

DRUG6 trials

Sponsors

Oregon Health and Science University, Baxalta now part of Shire, Children's Hospital Los Angeles, Emory University, Mayo Clinic

Conditions

BleedingCardiac DiseaseCardiovascular DiseaseHemophilia AHemophilia A With InhibitorHemophilia A or B With InhibitorsSurgery

Phase 1

FEIBA and Use of Blood Products in Cardiac Surgery

CompletedNCT02577614

Oregon Health and Science UniversityCardiovascular Disease

Start: 2016-02-29End: 2020-03-31Updated: 2020-07-14

Phase 2

FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients

WithdrawnNCT05020483

Mayo ClinicCardiac Disease

Start: 2021-10-31End: 2023-12-31Updated: 2022-12-05

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

RecruitingNCT07032792

Northwell HealthBleeding, Cardiac Disease, Surgery

Start: 2025-11-03End: 2029-11-01Target: 140Updated: 2026-03-11

Phase 3

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

CompletedNCT02764489

Baxalta now part of ShireHemophilia A or B With Inhibitors

Start: 2019-02-12End: 2021-12-27Updated: 2023-02-14

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

RecruitingNCT04563520

Emory UniversityHemophilia A

Start: 2026-09-01End: 2027-03-01Target: 5Updated: 2026-08-21

Phase 4

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Active, not recruitingNCT04205175

Children's Hospital Los AngelesHemophilia A With Inhibitor

Start: 2020-07-01End: 2022-10-31Target: 20Updated: 2022-03-09

Related Papers

Reduced Volume and Faster Infusion Rate of Activated Prothrombin Complex Concentrate: A Phase 3b/4 Trial in Adults with Hemophilia A with Inhibitors

TH Open2024-07-01

Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial.

2021-07-025 citations